Wed Jul 16 06:40:00 UTC 2025: ## Anthem Biosciences IPO Sees Strong Demand on Day Two, Subscription Reaches 1.03x

**Bengaluru, July 16, 2025** – The Initial Public Offering (IPO) of Bengaluru-based Contract Research, Development & Manufacturing Organization (CRDMO) Anthem Biosciences is off to a promising start, with the issue being subscribed 1.03 times on its second day, July 16, 2025. The bidding window opened yesterday, July 15, 2025, and has seen particular interest from Non-Institutional Investors (NII), who have subscribed 2.43 times. Retail investors subscribed 0.80 times their allotted portion, while Qualified Institutional Buyers (QIB) subscribed 0.39 times.

The IPO, which aims to raise ₹3,395.00 crores, is entirely an offer for sale of 5.96 crore shares. The price band has been fixed between ₹540 and ₹570 per share, with a minimum lot size of 26 shares, requiring a minimum investment of ₹14,040.

JM Financial Limited, Citigroup Global Markets India, J P Morgan India, and Nomura Financial Advisory and Securities (India) Pvt Ltd are acting as the book-running lead managers for the IPO, while Kfin Technologies Limited is the registrar.

Anthem Biosciences, founded in 2006, is a leading CRDMO offering end-to-end services across drug discovery, development, and manufacturing for both small molecules and biologics. The company boasts a diverse clientele of over 550 clients across 44 countries, with a strong presence in regulated markets like the US, Europe, and Japan. In FY25, Anthem Biosciences reported a revenue of ₹1,844.6 crore and a net profit of ₹451.3 crore.

The allotment process is expected to be finalized on Thursday, July 17, 2025, and the shares are tentatively scheduled to be listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on Monday, July 21, 2025.

According to a Business Standard Media Report dated July 15, 2025, the Grey Market Premium (GMP) for Anthem Biosciences stood at ₹116 at 10:00 a.m. on July 15th. This suggests a potential listing price of around ₹686, based on the upper end of the price band, potentially yielding a gain of 20.35% per share.

**Disclaimer:** *The Grey Market Premium (GMP) price is an unauthenticated market-related news and has no discernible basis. The information provided is for informational purposes only and investors are advised to conduct their own research before making any investment decisions. We do not engage in, trade, or deal in the grey market nor do we recommend or endorse trading in the grey market.*

It is important to note that the company will not receive any proceeds from the offer as it is entirely an Offer For Sale (OFS), with all proceeds going to the Promoter Selling Shareholder after deducting offer-related expenses and taxes.

Read More